

Practical Gynecology, 2nd Edition – Chapter 3 References

- *1. Erickson GF. An analysis of follicle development and ovum maturation. *Semin Reprod Endocrinol.* 1986;4:233.
2. **Lenton EA, et al.** Normal variation in the length of the follicular phase of the menstrual cycle: effect of chronological age. *Br J Obstet Gynaecol.* 1984;91(7):681-4.
- *3. **Fraser IS, et al.** A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. *Fertil Steril.* 2007;87(3):466-76. *An international group of experts on disorders of menstruation met in Washington D.C. to engage in international debate and consultation. There was almost-universal agreement that poorly defined terms of classical origin that are used in differing ways in the English medical language should be discarded and that these should be replaced by simple, descriptive terms with clear definitions that have the potential to be understood by health professionals and patients alike.*
4. **Joshi JV, et al.** Menstrual irregularities and lactation failure may precede thyroid dysfunction or goitre. *J Postgrad Med.* 1993;39(3):137-41.
5. **Goldsmith RE, et al.** The menstrual pattern in thyroid disease. *J Clin Endocrinol Metab.* 1952;12(7):846-55.
- *6. **Kouides PA, et al.** Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. *Fertil Steril.* 2005; 84(5):1345-51. *The evaluation of excessive menstrual bleeding carries a relatively high yield of discovering an underlying disorder of hemostasis in females. This review highlights important components in a structured history and outlines primary and secondary hematologic testing that should be considered in the evaluation of excessive menstrual bleeding.*
7. **Ash SJ, Farrell SA, Flowerdew G.** Endometrial biopsy in DUB. *J Reprod Med.* 1996;41(12):892-6.
- *8. **Langer RD, et al.** Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. *Postmenopausal Estrogen/Progestin Interventions Trial.* *N Engl J Med.* 1997; 337(25):1792-8.
- *9. **Youssif SN, McMillan DL.** Outpatient endometrial biopsy: the pipelle. *Br J Hosp Med.* 1995;54(5):198-201. A succinct summary of the safety and accuracy of the pipelle endometrial biopsy with and without transvaginal sonography as a technique for evaluation of endometrial adenocarcinoma.
- *10. **Kurman RJ, Kaminski PF, Norris HJ.** The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. *Cancer.* 1985;56(2):403-12.
11. **Zweizig S, et al.** Neoplasia associated with atypical glandular cells of undetermined significance on cervical cytology. *Gynecol Oncol.* 1997;65(2):314-8.

- *12. **Meuwissen JH, Oddens BJ, Klinkhamer PJ.** Endometrial thickness assessed by transvaginal ultrasound insufficiently predicts occurrence of hyperplasia during unopposed oestrogen use. *Maturitas*.1996; 24(1-2):21-30.
13. **O'Connell LP, et al.** Triage of abnormal postmenopausal bleeding: a comparison of endometrial biopsy and transvaginal sonohysterography versus fractional curettage with hysteroscopy. *Am J Obstet Gynecol.* 1998;178(5):956-61.
- *14. **Goldstein SR, et al.** Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. *Am J Obstet Gynecol.* 1997;177(1):102-8.
- *15. **Clark TJ, et al.** Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. *JAMA.* 2002;288(13):1610-21.
16. **Weber AM, et al.** Vaginal ultrasonography versus endometrial biopsy in women with postmenopausal bleeding. *Am J Obstet Gynecol.* 1997;177(4):924-9.
17. **Gay JD, Donaldson LD, Goellner JR.** False-negative results in cervical cytologic studies. *Acta Cytol.*1985;29(6):1043-6.
- *18. **Claessens EA, Cowell CA.** Acute adolescent menorrhagia. *Am J Obstet Gynecol.* 1981;139(3):277-80.
19. **Denes FT, et al.** The laparoscopic management of intersex patients: the preferred approach. *BJU Int.* 2005;95(6):863-7.
20. **Sklar CA, et al.** Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. *J Natl Cancer Inst.* 2006;98(13):890-6.
21. **Massin N, et al.** Idiopathic premature ovarian failure in 63 young women. *Horm Res.* 2006;65(2): 89-95.
- *22. **Kauffman RP, Castracane VD.** Premature ovarian failure associated with autoimmune polyglandular syndrome: pathophysiological mechanisms and future fertility. *J Womens Health (Larchmt).* 2003;12(5):513-20. This is a case report of a 26-year-old woman with autoimmune polyglandular syndromes (APS) type II with autoimmune premature ovarian failure. It is accompanied by a respectable review of autoimmune polyglandular syndromes including the current status of molecular genetics and immunotherapy.
23. **Wittenberger MD, et al.** The FMR1 premutation and reproduction. *Fertil Steril.* 2007;87(3):456-65.
24. **Vandborg M, Lauszus FF.** Premature ovarian failure and pregnancy. *Arch Gynecol Obstet.* 2006;273(6):387-8.
25. **Maltaris T, et al.** The effect of cancer treatment on female fertility and strategies for preserving fertility. *Eur J Obstet Gynecol Reprod Biol.* 2007;130(2):148-55.

26. **Marhhom E, Cohen I.** Fertility preservation options for women with malignancies. *Obstet Gynecol Surv*, 2007;62(1):58-72.
- *27. **Gibney J, Smith TP, McKenna TJ.** Clinical relevance of macroprolactin. *Clin Endocrinol (Oxf)*. 2005;62(6):633-43. *This paper alerts clinicians to the frequent interference of laboratory serum prolactin measurements by “macroprolactin”, a biologically inactive molecule. Up to a quarter of diagnoses of hyperprolactinemia may be false positives, and thus most patients found to have high serum prolactin values should next undergo serum macroprolactin measurements to exclude high physiologic levels.*
28. **Cannavo S, et al.** Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. *J Endocrinol Invest*. 1999;22(5):354-9.
29. **New MI.** Extensive clinical experience: nonclassical 21-hydroxylase deficiency. *J Clin Endocrinol Metab*. 2006;91(11):4205-14.
- *30. **Broekmans FJ, et al.** PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. *BJOG*. 2006;113(10):1210-7.
31. **Azziz R, et al.** The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab*. 2004;89(6):2745-9.
32. **Crosignani PG, et al.** Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. *Hum Reprod*. 2003;18(9):1928-32.
33. **Escobar-Morreale HF, et al.** The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. *J Clin Endocrinol Metab*. 2005;90(12):6364-9.
- *34. **Guzick DS.** Polycystic ovary syndrome. *Obstet Gynecol*. 2004;103(1):181-93. *The etiology, diagnosis, and treatment of women with polycystic ovarian syndrome is presented. Behavioral weight management and general health monitoring is stressed as a central component of the overall treatment strategy.*
- *35. **Setji TL, Brown AJ.** Polycystic ovary syndrome: diagnosis and treatment. *Am J Med*. 2007;120(2):128-32. *This article reviews the diagnosis, clinical manifestations, metabolic complications, and treatment of the polycystic ovary syndrome. A table summarizing treatment recommendations is provided.*
36. **Legro RS.** Diabetes prevalence and risk factors in polycystic ovary syndrome. *Obstet Gynecol Clin North Am*. 2001;28(1):99-109.
37. **Dunaif A.** Insulin resistance in women with polycystic ovary syndrome. *Fertil Steril*. 2006;86 Suppl 1:S13-4.

- *38. **Azziz R.** The Evaluation And Management Of Hirsutism. *Obstet Gynecol.* 2003;101(5 Pt 1): 995-1007.
39. **Baakdah H, Tulandi T.** Uterine fibroid embolization. *Clin Obstet Gynecol.* 2005;48(2):361-8.
- *40. **Sharp HT.** Assessment of new technology in the treatment of idiopathic menorrhagia and uterine leiomyomata. *Obstet Gynecol.* 2006;108(4):990-1003.
- *41. **DeWaay DJ, et al.** Natural history of uterine polyps and leiomyomata. *Obstet Gynecol.* 2002;100(1):3-7. *To estimate the incidence and regression rates of uterine leiomyomata and polyps in a cohort of asymptomatic women, saline infusion sonography was performed twice in a cohort of 64 initially asymptomatic women. Small uterine polyps frequently regressed spontaneously, whereas larger polyps were more likely to persist and were associated with the development of abnormal bleeding. Smaller leiomyomata in older (premenopausal) women also regressed whereas larger leiomyomata tended to grow while often remaining asymptomatic.*
42. **Clark TJ, et al.** Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. *BJOG.* 2002;109(3):313-21.
43. **Richards-Kustan CJ, Kase NG.** Diagnosis and management of perimenopausal and postmenopausal bleeding. *Obstet Gynecol Clin North Am.* 1987;14(1):69-89.
44. **Van den Bosch T, et al.** Combining vaginal ultrasonography and office endometrial sampling in the diagnosis of endometrial disease in postmenopausal women. *Obstet Gynecol.* 1995;85(3):349-52.
45. **Gimpelson RJ, Rappold HO.** A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases. *Am J Obstet Gynecol.* 1988;158(3 Pt 1):489-92.
- *46. **Horn LC, et al.** Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. *Int J Gynecol Cancer.* 2004; 14(2):348-53.
47. **Rackow BW, Arici A.** Endometrial cancer and fertility. *Curr Opin Obstet Gynecol.* 2006. 18(3):245-52.
- *48. **Marjoribanks J, Lethaby A, Farquhar C.** Surgery versus medical therapy for heavy menstrual bleeding. *Cochrane Database Syst Rev.* 2006(2):CD003855. *To compare the effectiveness, safety, and acceptability of surgery versus medical therapy for heavy menstrual bleeding, the authors performed a systematic review of controlled randomized trials comparing conservative surgery or hysterectomy versus medical therapy.*
- *49. **Iyer V, Farquhar C, Jepson R.** Oral contraceptive pills for heavy menstrual bleeding. *Cochrane Database Syst Rev.* 2000;(2):CD000154.

50. **Lethaby AC, Augood, Duckitt K.** Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. *Cochrane Database Syst Rev.* 2002;(1):CD000400.
51. **Colacurci N, et al.** Short-term use of Goserelin depot in the treatment of dysfunctional uterine bleeding. *Clin Exp Obstet Gynecol.* 1995;22(3):212-9.
52. **Franke HR, et al.** Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial. *Gynecol Endocrinol.* 2006;22(12):692-7.
53. **Beaumont H, et al.** Danazol for heavy menstrual bleeding. *Cochrane Database Syst Rev.* 2002;(2):CD001017.
54. **Shirk, GJ.** Minimally invasive surgery for ablation of the endometrium. *Clin Obstet Gynecol.* 2005;48(2):325-36.
55. **Gurtcheff SE, Sharp, HT.** Complications associated with global endometrial ablation: the utility of the MAUDE database. *Obstet Gynecol,* 2003;102(6):1278-82.